JSPRWHIGH SIGNALFINANCIAL10-K

JSPRW experienced severe financial deterioration with stockholders' equity collapsing 93% to $4.2M while operating cash burn increased 23% to $77.2M, creating a critical funding situation.

The company's equity base has been almost entirely depleted while cash burn has accelerated, indicating JSPRW is rapidly approaching a potential liquidity crisis. With only $28.7M in cash remaining and burning over $77M annually, the company likely has less than 5-6 months of runway without immediate capital infusion.

Comparing 2026-03-30 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

JSPRW's financial position deteriorated dramatically across all key metrics, with total assets declining 55% to $35.8M and cash reserves falling 60% to $28.7M while total liabilities surged 74% to $31.6M. The company's R&D expenses increased 13% to $63.1M and operating cash outflows worsened to $77.2M, creating an unsustainable burn rate relative to remaining cash reserves. This financial profile signals an urgent need for additional funding or strategic alternatives to avoid potential insolvency.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
-93.3%
$61.7M$4.2M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Total Liabilities
Balance Sheet
+73.5%
$18.2M$31.6M

Liabilities grew 73.5% — significant increase in debt or obligations, assess impact on financial flexibility.

Cash & Equivalents
Balance Sheet
-59.9%
$71.6M$28.7M

Cash declined 59.9% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Assets
Balance Sheet
-55.2%
$79.9M$35.8M

Total assets contracted 55.2% — asset sales, write-downs, or balance sheet optimization underway.

Current Assets
Balance Sheet
-54.3%
$75.8M$34.6M

Current assets declined 54.3% — monitor working capital adequacy and short-term liquidity.

Operating Cash Flow
Cash Flow
-23.3%
-$62.6M-$77.2M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Current Liabilities
Balance Sheet
-13.4%
$15.2M$13.2M

Current liabilities reduced — improved short-term financial position and working capital health.

R&D Expense
P&L
+13%
$55.8M$63.1M

R&D investment increased 13% — signals commitment to future product development, though near-term margin impact.

Operating Income
P&L
-10%
-$76.2M-$83.9M

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-02-28
ADDED
Certain Relationships and Related Transactions, and Director Independence 119 PART IV Item 14.
Some of these risks and uncertainties may in the future be amplified, and there may be additional risks that we consider immaterial or which are unknown.
BUSINESS Overview We are a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria ( CSU ), Chronic Inducible Urticaria ( CIndU ) and asthma and we continue to consider additional indications in mast cell driven diseases for potential future development.
We have also historically explored development programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as stem cell transplant conditioning regimens, but those programs have been discontinued and we are exclusively focused on mast cell driven diseases.
Development highlights include: CSU - BEACON Study We commenced the Phase 1b/2a BEACON study in CSU in late 2023.
+7 more — sign up free →
REMOVED
Certain Relationships and Related Transactions, and Director Independence 128 PART IV Item 14.
References to Old Jasper refer to the private Delaware corporation that is now our wholly-owned subsidiary and named Jasper Tx Corp.
On September 24, 2021, we consummated the previously announced Business Combination (as defined below) (pursuant to the Business Combination Agreement, dated May 5, 2021, by and among AMHC, Ample Merger Sub, Inc.
Pursuant to the terms of the Business Combination Agreement, a business combination (herein referred to as the Business Combination or Reverse Recapitalization for accounting purposes) between AMHC and Old Jasper was effected through the merger of Merger Sub with and into Old Jasper with Old Jasper surviving as AMHC s wholly-owned subsidiary.
There may be additional risks that we consider immaterial or which are unknown.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →